Roche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis optica spectrum disorder (NMOSD), setting up regulatory filings. The interleukin-6-targeting ...
A team of researchers from Germany demonstrated that aquaporin 4 (AQP4)-specific T cells dictate the localization of neuromyelitis optica spectrum disorder (NMOSD) lesions in the central nervous ...
Current disability scores fall short of having sufficient NMOSD-specific domains to characterize and predict disability progression. In disorders such as neuromyelitis optica spectrum disorder (NMOSD) ...
Background and Objectives: Low free triiodothyronine (FT3) is usually associated with worse functional outcome in critical illness; however, the information on thyroid dysfunction and autoimmune ...
It's also called neuromyelitis optica spectrum disorder (NMOSD) or Devic's disease. NMO specifically affects the myelin, which is the insulation around the nerves. NMO mainly affects the spinal cord ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback